EUVIMEDEUVIMED entdecken
Vergleichsstudie

Efficacy and Safety of Direct Oral Anticoagulants (DOACs) Versus Enoxaparin For Extended Thromboprophylaxis Following Sleeve Gastrectomy

Avery Brown, Elizabeth S Li, Suhani Patel, Allan Massie, Peculiar Ihunwo, Ariel Schaap, Moyosore Alade, Christine J Ren-Fielding, Eduardo Somoza, Babak J Orandi, Dorry Segev, Manish Parikh und 1 weitere

Surgery for Obesity and Related Diseases · 2026

DOI: 10.1016/j.soard.2026.02.005 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Surgery for Obesity and Related Diseases, 2026. Verfasst von Avery Brown und 12 weiteren Autor:innen. Beteiligte Einrichtung: Bellevue Division of Bariatric and General Surgery, NYC Health + Hospitals, New York, New York; Department of Surgery, NYU Grossman School of Medicin…. Hauptthemen laut MEDLINE: Enoxaparin, Gastrectomy, Pyridones, Venous Thromboembolism. Die Arbeit nennt 36 Literaturangaben. Gefördert von: NIDDK NIH HHS, National Institutes of Health, National Center for Advancing Translational Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Extended-course enoxaparin is increasingly used after bariatric surgery to prevent venous thromboembolism (VTE), the leading cause of death after bariatric surgery. Direct oral anticoagulants are widely used for extended thromboprophylaxis outside of bariatric surgery and offered to patients in our program who cannot tolerate or obtain enoxaparin. We evaluated the safety and efficacy of apixaban 2.5 mg twice daily relative to a weight-based dose of enoxaparin 40 mg or 60 mg twice daily for 30 days after discharge following sleeve gastrectomy. METHODS: Patients aged ≥18 years who underwent laparoscopic sleeve gastrectomy from 2019 to 2024 at a single high-volume urban academic center were included. Bleeding and thrombosis outcomes within 30 days were compared between patients receiving enoxaparin 40 mg twice daily or apixaban 2.5 mg twice daily. Weighted modified Poisson analyses were used to obtain covariate balance and assess differences in bleeding and thrombosis events. RESULTS: A total of 5921 patients were included for analysis (5274 enoxaparin 40 mg twice daily, 486 enoxaparin 60 mg twice daily, and 161 apixaban 2.5 mg twice daily). The 30-day thrombosis rate was significantly lower with enoxaparin versus apixaban (.1% versus 1.9%, P < .001). The composite outcome (VTE, portomesenteric venous thrombosis, and major/minor bleeding) was also significantly lower with enoxaparin versus apixaban (1.7% versus 5.6%, P < .01). In adjusted analyses, apixaban was associated with a relative risk of 12.09 for thrombosis (95% confidence interval [CI], 5.71-31.18), 1.93 for bleeding (95% CI, 1.27-3.00), and 2.59 (95% CI, 2.06-3.27) for any adverse outcome relative to enoxaparin. CONCLUSION: Enoxaparin is associated with both lower thrombosis and bleeding rates compared with apixaban for extended thromboprophylaxis after sleeve gastrectomy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EnoxaparinGastrectomyPyridonesVenous ThromboembolismPyrazolesAnticoagulantsBariatric SurgeryPostoperative ComplicationsFactor Xa InhibitorsHumansFemaleMaleMiddle AgedAdultAdministration, OralRetrospective StudiesTreatment OutcomeObesity, Morbid

Stichwörter der Autor:innen

ApixabanChemoprophylaxisEnoxaparinExtended thromboprophylaxisSleeve gastrectomyVenous thromboembolism

Substanzen

EnoxaparinPyridonesapixabanPyrazolesAnticoagulantsFactor Xa Inhibitors

Autor:innen und Institutionen

  • Bellevue Division of Bariatric and General Surgery, NYC Health + Hospitals, New York, New York; Department of Surgery, NYU Grossman School of Medicine, New York, New York.
  • Department of Surgery, NYU Grossman School of Medicine, New York, New York.
  • Department of Surgery, NYU Grossman School of Medicine, New York, New York; Center for Surgical and Transplant Applied Research, NYU Grossman School of Medicine, New York, New York.
  • Bellevue Division of Bariatric and General Surgery, NYC Health + Hospitals, New York, New York.
  • Division of Hematology, NYU Grossman School of Medicine, New York, New York; Department of Medicine, NYU Grossman School of Medicine, New York, New York.
  • Department of Surgery, NYU Grossman School of Medicine, New York, New York; Center for Surgical and Transplant Applied Research, NYU Grossman School of Medicine, New York, New York; Department of Medicine, NYU Grossman…

Förderung

  • NIDDK NIH HHS
  • National Institutes of Health
  • National Center for Advancing Translational Sciences
  • New York University

Zitieren

APA

Brown, A., Li, E. S., Patel, S., Massie, A., Ihunwo, P., Schaap, A., Alade, M., Ren-Fielding, C. J., Somoza, E., Orandi, B. J., Segev, D., Parikh, M., & Chhabra, K. R. (2026). Efficacy and Safety of Direct Oral Anticoagulants (DOACs) Versus Enoxaparin For Extended Thromboprophylaxis Following Sleeve Gastrectomy. Surgery for Obesity and Related Diseases. https://doi.org/10.1016/j.soard.2026.02.005

Vancouver

Brown A, Li ES, Patel S, Massie A, Ihunwo P, Schaap A, et al. Efficacy and Safety of Direct Oral Anticoagulants (DOACs) Versus Enoxaparin For Extended Thromboprophylaxis Following Sleeve Gastrectomy. Surgery for Obesity and Related Diseases. 2026. doi:10.1016/j.soard.2026.02.005

BibTeX
@article{Brown2026,
  author = {Brown, Avery and Li, Elizabeth S and Patel, Suhani and Massie, Allan and Ihunwo, Peculiar and Schaap, Ariel and Alade, Moyosore and Ren-Fielding, Christine J and Somoza, Eduardo and Orandi, Babak J and Segev, Dorry and Parikh, Manish and Chhabra, Karan R},
  title = {Efficacy and Safety of Direct Oral Anticoagulants (DOACs) Versus Enoxaparin For Extended Thromboprophylaxis Following Sleeve Gastrectomy},
  journal = {Surgery for Obesity and Related Diseases},
  year = {2026},
  doi = {10.1016/j.soard.2026.02.005}
}
Kostenlos starten →